Intranasal administration of recombinant human cartilage glycoprotein-39 as a treatment for rheumatoid arthritis: a phase II, multicentre, double-blind, randomised, placebo-controlled, parallel-group, dose-finding trial.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples